We report a case of epithelial ovarian cancer, which presented with lumbar vertebral metastasis soon after treatment, as a part of Ranjeet Bajpai, Punita Lal distant spread. This patient was then treated by palliative radiotherapy and put on second line chemotherapy i.e., Topotecan. She responded to treatment well.
INTRODUCTION
1986 staging system). She was advised for adjuvant chemotherapy at that time, which she did not take. Ovarian cancer is the fourth most common type of Three months later she developed distention of female cancer and fifth leading cause of cancer death abdomen along with vague dyspeptic symptoms. in women in the United States. [1] In India, the ICMR She then reported to the Department of Radiotherapy registry reports the crude incidence rate of this Sanjay Gandhi Postgraduate Institute of Medical cancer as 4.2 per 100,000 women, making it the Sciences for further management. fourth most common malignancy in women.
[2] Main route of dissemination in ovarian cancer is by On examination at that time, she was of average transcoelomic spread and through lymphatics.
built with karnofsky performance status of 80. There Hematogenous spread is uncommon. [3, 4] was no evidence of pallor, icterus or lymphadenopathy. Examination of abdomen showed Metastasis to bones from these tumors is rare (0.1-presence of free fluid with no associated 0.12%) and is reported in a few series. [5, 6] We have organomegaly or palpable lump. Pouch of Douglas registered 189 ovarian cancers in the department of was free on per vaginal examination. She was radiotherapy, SGPGI, in the last 15 years and have investigated with a contrast-enhanced computed not encountered single case of bone metastasis so tomography (CECT) scan of abdomen and pelvis, far. This case was unique in presenting vertebral which showed moderate ascitis with no residual metastasis soon after chemotherapy. disease or enlarged pelvic or para aortic lymph nodes and had postoperative changes.
CASE REPORT
CA 125 was done at that time and it was raised to A 45-year-old premenopausal lady presented to a 510U/ml. She was diagnosed to have progression of disease. Adjuvant chemotherapy i.e., Paclitaxel and ) at three weekly intervals. The patient was hospitalized for chemotherapy, which was given with proper hydration and under antiemetic cover. She tolerated chemotherapy well and was on regular follow-up thereafter. Her CA-125 levels came down to 24U/ml at the end of treatment. Five months after completion of treatment, she complained of backache and abdominal pain and was advised for X-ray lumbar spine, bone scan, liver scan and CECT scan of abdomen. X-ray-lateral view [ Figure 1 ] and bone scan [ Figure 2 ] revealed a solitary metastasis on L2 vertebra. CECT scan of the abdomen [ Figure 3 ] showed a space occupying lesion in the postero- 
DISCUSSION
Epithelial ovarian cancer should not be considered a disease that remains confined to the pelvis and abdomen. Like other adenocarcinomas this disease has significant potential for distant metastasis. [3] Bony metastasis from epithelial ovarian malignancies is anecdotal and has been reported rarely in literature. Mode of spread appears to be hematogenous although no definite route has been documented in literature.
In an autopsy series, Dauplat et al analyzed 336 patients of distant metastasis from ovarian cancers. Of these, four patients had bone metastasis, two of which belonged to thoracic vertebra; one to the clavicle and one had bone marrow involvement. None of the patients in this series had bone metastasis as first site of presentation. According to the authors bony metastasis is rarest to be presented as first site and median time to development ranged from 13-49 months. [3] In the present case report as well, bone involvement appears to be a part of hematogenous spread since both liver and bone were involved.
Rose et al in their autopsy series studied the metastatic pattern in 428 ovarian cancers and correlated different histologies with sites of metastasis. The incidence of bony metastasis was 0.06 0. 19% with epithelial histology. This reflects the rarity of bone involvement in this malignancy. There was no difference, however, in the spread pattern with different histological subtypes. [5] Fadi et al did a clinico pathological audit of bone metastasis from different gynecological carcinomas. They analyzed 305 patients, of which 113 were ovarian cancers. Skeletal metastasis was seen in seven patients. Five were documented as postmortem findings and only two showed up radiologically and in premortem setting. Bone metastasis was seen in high grades tumors only. Most common site observed was thoracic vertebra, followed by clavicle and axial skeleton. [7] In the present case too, high-grade features were documented in the TAH-BSO specimen. Lumbar vertebral involvement, which is less common than thoracic region, was seen in this case.
Rose et al had observed that presence of lymph nodes within the pelvis and para aortic regions were associated with greater incidence of bone metastasis as compared to absent lymphadenopathy i.e., 0.14% to 0.02%. [5] The present case did not have any lymph nodes yet bony secondaries developed five months following treatment.
Although there was no histological proof of spread to the vertebra but radiological and scintigraphic evidence was considered sufficient proof of dissemination to the bone. Pain palliation and growth restraint was done as one would do in any epithelial malignancy. Radiotherapy along with single agent Topotecan has been found to be effective thus far. ) .
